Lv1
10 积分 2025-02-26 加入
The diverse functions of the PD1 inhibitory pathway
19天前
已完结
Cost-effectiveness of Laparoscopic vs Open Gastrectomy for Gastric Cancer
24天前
已完结
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
26天前
已完结
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
1个月前
已完结
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
1个月前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
4个月前
已完结
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
4个月前
已完结
皖公网安备34019202002308
